Home › Merck Provides Update on IMPROVE-IT Trial
 

Keywords :   


Merck Provides Update on IMPROVE-IT Trial

2013-03-12 13:00:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that the Data Safety Monitoring Board (DSMB) of the IMPROVE-IT trial has completed its planned review of study data and recommended that the study continue. The study design calls for the collection of 5,250 clinical endpoints. Merck remains blinded to the actual results of this analysis and to other IMPROVE-IT safety and efficacy data. Language:  English Contact HTML:  MerckMedia:Kelley Dougherty, 908-423-4291Skip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: update trial merck update merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.09California approves 'click or call to cancel' subscriptions bill
30.09EU clears Swisscom's acquisition of Vodafone Italia
30.09Barb extends campaign planning to include discovery+ and Netflix
30.09Samsung accused of obstructing Fortnite downloads
30.09UK to finish with coal power after 142 years
30.09Farm Progress America, September 30, 2024
30.09Farm Progress America, September 30, 2024
30.09Tropical Depression Twelve Graphics
More »